• Explore /
  • Poster
  • / Trial in progress: Open-label, randomized, comparative phase 2/3 study of combination immunotherapy plus standard-of-care chemotherapy and SBRT versus standard-of-care chemotherapy for the treatment of locally advanced or metastatic pancreatic cancer.

Trial in progress: Open-label, randomized, comparative phase 2/3 study of combination immunotherapy plus standard-of-care chemotherapy and SBRT versus standard-of-care chemotherapy for the treatment of locally advanced or metastatic pancreatic cancer.

Abstract Poster

Authors

null

Tara Elisabeth Seery

Chan Soon Shiong Institute for Medicine, El Segundo, CA

Tara Elisabeth Seery , Chaitali Singh Nangia , Leonard S. Sender , Sandeep K. Reddy , Patrick Soon-Shiong

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Pancreatic Cancer

Clinical Trial Registration Number

NCT04390399

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr TPS4174)

DOI

10.1200/JCO.2021.39.15_suppl.TPS4174

Abstract #

TPS4174

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Akihiro Ohba

Poster

2022 ASCO Gastrointestinal Cancers Symposium

A phase II study of nivolumab in combination with modified FOLFIRINOX for metastatic pancreatic cancer.

A phase II study of nivolumab in combination with modified FOLFIRINOX for metastatic pancreatic cancer.

First Author: Makoto Ueno

First Author: Angela Tatiana Alistar

First Author: Kazuo Watanabe